Non-small-cell lung cancer
Conditions
Interventions
Eligibility criteria were histologically or cytologically confirmed NSCLC, no prior treatment, ECOG performance status (PS) 0-2 and age >
70 years. PTX (90 or 100 mg/m2) were administered in combination with a fixed dose of CBDCA (area under the concentration-time curve
AUC of 3) on day 1 and 15 (every two weeks).
Sponsors
Shimane University Faculty of Medicine, Division of Clinical Oncology and Respiratory Medicine
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1)Histology/cytology-proven non-small cell lung cancer, age of 70 years or over 2)No prior chemotherapy or prior 1-regimen of EGFR TKI 3)ECOG performance status of 0-2 4)Adequate reserves for marrow, renal, hepatic, and pulmonary functions 5)Acquisition of written informed consent
Exclusion criteria
Exclusion criteria: 1)Previous 2-regimen chemotherapy or 1-regimen of EGFR-TKI 2)Concurrent chemoradiotherapy 3)Serious infections 4)Ssymptomatic brain metastasis 5)Massive pericardial, pleural effusion, or ascites 6)Serious clinical probrems 7)Previous drug allergy or alchol allergy 8)Hoped to be pregnant/ nursing 9)Those judged to be not suitable by the attending physician
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Maximum Tolerated Dose of CBDCA+PTX bi-weekly therapy | — |
Secondary
| Measure | Time frame |
|---|---|
| Anti tumor efficacy, Quality of life | — |
Countries
Japan
Outcome results
None listed